107 related articles for article (PubMed ID: 11072153)
1. A cost-outcome analysis of adjuvant postmastectomy locoregional radiotherapy in premenopausal node-positive breast cancer patients.
Dunscombe P; Samant R; Roberts G
Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):977-82. PubMed ID: 11072153
[TBL] [Abstract][Full Text] [Related]
2. Decision-analytic model and cost-effectiveness evaluation of postmastectomy radiation therapy in high-risk premenopausal breast cancer patients.
Lee JH; Glick HA; Hayman JA; Solin LJ
J Clin Oncol; 2002 Jun; 20(11):2713-25. PubMed ID: 12039934
[TBL] [Abstract][Full Text] [Related]
3. A cost-outcome analysis of adjuvant postmastectomy locoregional radiotherapy in high-risk postmenopausal breast cancer patients.
Samant R; Dunscombe P; Roberts G
Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1376. PubMed ID: 11503614
[No Abstract] [Full Text] [Related]
4. Cost-effectiveness Analysis Comparing Conventional, Hypofractionated, and Intraoperative Radiotherapy for Early-Stage Breast Cancer.
Deshmukh AA; Shirvani SM; Lal L; Swint JM; Cantor SB; Smith BD; Likhacheva A
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059428
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of routine radiation therapy following conservative surgery for early-stage breast cancer.
Hayman JA; Hillner BE; Harris JR; Weeks JC
J Clin Oncol; 1998 Mar; 16(3):1022-9. PubMed ID: 9508186
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects.
Au HJ; Golmohammadi K; Younis T; Verma S; Chia S; Fassbender K; Jacobs P
Breast Cancer Res Treat; 2009 Apr; 114(3):579-87. PubMed ID: 18443903
[TBL] [Abstract][Full Text] [Related]
7. Intrinsic subtypes and benefit from postmastectomy radiotherapy in node-positive premenopausal breast cancer patients who received adjuvant chemotherapy - results from two independent randomized trials.
Laurberg T; Tramm T; Nielsen T; Alsner J; Nord S; Myhre S; Sørlie T; Leung S; Fan C; Perou C; Gelmon K; Overgaard J; Voduc D; Prat A; Cheang MCU
Acta Oncol; 2018 Jan; 57(1):38-43. PubMed ID: 29172851
[TBL] [Abstract][Full Text] [Related]
8. Is the use of radiation therapy after mastectomy cost-effective?
Hayman JA; Hillner BE
Semin Radiat Oncol; 1999 Jul; 9(3):287-91. PubMed ID: 10378968
[TBL] [Abstract][Full Text] [Related]
9. The INTRABEAM® Photon Radiotherapy System for the adjuvant treatment of early breast cancer: a systematic review and economic evaluation.
Picot J; Copley V; Colquitt JL; Kalita N; Hartwell D; Bryant J
Health Technol Assess; 2015 Aug; 19(69):1-190. PubMed ID: 26323045
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness assessment of lumpectomy cavity boost in elderly women with early stage estrogen receptor positive breast cancer receiving adjuvant radiotherapy.
Lester-Coll NH; Rutter CE; Evans SB
Radiother Oncol; 2016 Apr; 119(1):52-6. PubMed ID: 26867968
[TBL] [Abstract][Full Text] [Related]
11. Subgroup Economic Evaluation of Radiotherapy for Breast Cancer After Mastectomy.
Wan X; Peng L; Ma J; Chen G; Li Y
Clin Ther; 2015 Nov; 37(11):2515-2526.e5. PubMed ID: 26475419
[TBL] [Abstract][Full Text] [Related]
12. Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis.
Rocchi A; Verma S
Support Care Cancer; 2006 Sep; 14(9):917-27. PubMed ID: 16596419
[TBL] [Abstract][Full Text] [Related]
13. Assessing the cost-effectiveness of postmastectomy radiation therapy.
Marks LB; Hardenbergh PH; Winer ET; Prosnitz LR
Int J Radiat Oncol Biol Phys; 1999 Apr; 44(1):91-8. PubMed ID: 10219800
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
[TBL] [Abstract][Full Text] [Related]
16. Overview of randomized trials in high risk breast cancer patients treated with adjuvant systemic therapy with or without postmastectomy irradiation.
Overgaard M
Semin Radiat Oncol; 1999 Jul; 9(3):292-9. PubMed ID: 10378969
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
Liberato NL; Marchetti M; Barosi G
J Clin Oncol; 2007 Feb; 25(6):625-33. PubMed ID: 17308267
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of adding an electron-beam boost to tangential radiation therapy in patients with negative margins after conservative surgery for early-stage breast cancer.
Hayman JA; Hillner BE; Harris JR; Pierce LJ; Weeks JC
J Clin Oncol; 2000 Jan; 18(2):287-95. PubMed ID: 10637242
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis.
Wolowacz SE; Cameron DA; Tate HC; Bagust A
J Clin Oncol; 2008 Feb; 26(6):925-33. PubMed ID: 18281666
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
